News

Alexion Receives Positive Opinion from EU’s CHMP for Soliris to Treat Subgroup of gMG Patients

Alexion Pharmaceuticals has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion to extend the approved indication of Soliris (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) to patients who are anti-acetylcholine receptor (AChR)…

Researchers Gain Insight Into How Myasthenia Gravis Antibodies Destroy Receptor Vital to Movement

University of Southern California researchers have gained insight into how antibodies connected with a disease known as myasthenia gravis destroy a receptor crucial to movement. Their findings may give scientists clues about how to prevent the disease. The study, “Structural insights into the molecular mechanisms of…